William Robertson, MD
Medical Oncology · Searcy, ARNPI 1740404904
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 277 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,431 and has fallen 65.0% since, to $501 in 2025.
Across 277 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$605
- GSK$476
- AbbVie$429
- Pfizer$265
- Bristol Myers Squibb$224
- AstraZeneca$205
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,19696%
- Education$1974%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 39 | $605 |
| GSK | 26 | $476 |
| AbbVie | 20 | $429 |
| Pfizer | 20 | $265 |
| Bristol Myers Squibb | 14 | $224 |
| AstraZeneca | 14 | $205 |
| E.r. Squibb & Sons, L.L.C. | 18 | $192 |
| Seagen Inc. | 11 | $157 |
| Pharmacyclics LLC, An Abbvie Company | 9 | $154 |
| Johnson & Johnson(2 entities) | 8 | $141 |
| Eisai Inc. | 11 | $129 |
| Amgen | 8 | $127 |
| Daiichi Sankyo Inc. | 8 | $123 |
| Astellas Pharma US Inc | 7 | $118 |
| Merck | 8 | $113 |
| Gilead | 6 | $98 |
| Sanofi | 7 | $98 |
| Genentech USA, Inc. | 6 | $86 |
| Puma Biotechnology, Inc. | 5 | $83 |
| Incyte Corporation | 2 | $78 |
| Lilly USA, LLC | 5 | $74 |
| Beigene USA, Inc. | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Bayer | 2 | $36 |
| EMD Serono, Inc. | 2 | $31 |
| Taiho Oncology, Inc. | 2 | $27 |
| Epizyme, Inc. | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Tesaro, Inc. | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Array Biopharma Inc | 1 | $19 |
| CTI Biopharma Corp. | 1 | $18 |
| Dendreon Pharmaceuticals LLC | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Rigel Pharmaceuticals, Inc. | 1 | $15 |
| AVEO Pharmaceuticals, Inc. | 1 | $15 |
| Mirati Therapeutics, Inc. | 1 | $15 |
| Dova Pharmaceuticals | 1 | $12 |
| Exelixis Inc. | 1 | $11 |
How this compares
$4,393 in reported general payments places this provider in the 55th percentile of 20 medical oncology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 28 | $281,826 |
| ImbruvicaIbrutinib | 12 | $191,801 |
| Abiraterone Acetate | 13 | $25,101 |
| EliquisApixaban | 33 | $18,475 |
| Exemestane | 24 | $2,292 |
| Oxycodone Hcl | 90 | $2,156 |
| Ondansetron OdtOndansetron | 53 | $1,943 |
| Morphine Sulfate ErMorphine Sulfate | 12 | $1,372 |
| Letrozole | 69 | $1,202 |
| Morphine Sulfate | 12 | $1,005 |
| Prochlorperazine Maleate | 36 | $991 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 17 | $935 |
| Fluconazole | 28 | $706 |
| Hydroxyurea | 32 | $541 |
| Potassium Chloride | 12 | $322 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $47 | $281,82628 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $154 | $191,80112 claims |
| PfizerEliquis | $265 | $18,47533 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 20 medical oncology providers in Arkansas.
Other medical oncology in Searcy
- Stephen ToothakerSearcy$19K
- Ryan KochSearcy$15K
- Muthu KumaranLittle Rock$193K
- Sunilkumar KakadiaHot Springs$31K
- Cesar Gentille SanchezLittle Rock$29K
- Zaki SammanFort Smith$9K
- Kristen SagerMena$8K
- Chen HuangHarrison$5K
- Marc MonteJonesboro$2K
- Shadiqul HoqueNorth Little Rock$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.